Skip to main content

Ankylosing Spondylitis

Featured Article
“Because persistence with the same anti-TNF drug in second-line treatment decreases the overall disease-associated costs compared with non-persistence, this aspect … merits consideration by…
“The cost of AS-related total medical care significantly increased medical cost savings from 24.85% to 35.52% following TNFi dose reduction,” researchers concluded.
Back to Top